EGFR and pachyonychia congenita: Current targeted therapies, including the epidermal growth factor receptor (EGFR) inhibitor erlotinib and the neurotrophic tyrosine receptor kinase (NTRK)  inhibitors larotrectinib and entrectinib, are given to advanced-stage PC patients in combination with standard of care drugs to slow the progression of the tumor.